1. Volume 120, Issue 3, Pages 594-606 (February 2001)
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient 
Loren Laine 
Gastroenterology 
Volume 120, Issue 3, Pages (February 2001)
DOI: /gast
Copyright © 2001 American Gastroenterological Association Terms and Conditions

2. Fig. 1
Double-blind endoscopic trials of medical cotherapies for prevention of NSAID-induced ulcers. (A) Six-month trial of ranitidine, 150 mg twice daily, vs. omeprazole, 20 mg daily, in NSAID users with recent ulcer or >10 erosions.72 (B) Twelve-week trial of misoprostol, 200 μg 4 times daily, vs. placebo in arthritis patients without recent ulcer.73 *P < 0.05.
Gastroenterology  , DOI: ( /gast )
Copyright © 2001 American Gastroenterological Association Terms and Conditions

3. Fig. 2
Double-blind endoscopic trials of coxibs in patients with arthritis. (A) Combined results from 2 identical 24-week studies (placebo for 16 weeks) of placebo (▨, n = 340); rofecoxib, 25 mg (■, n = 373) or 50 mg (□, n = 360) daily; or ibuprofen, 800 mg 3 times daily (▩, n = 354) in patients with osteoarthritis.10,11 *P < vs. placebo, rofecoxib 25 and 50 mg. (B) 12-Week trial of placebo; celecoxib, 100, 200, or 400 mg twice daily; or naproxen, 500 mg twice daily, in patients with rheumatoid arthritis.12 *P < 0.01 vs. other groups. (C) 24-Week trial of celecoxib, 200 mg twice daily, or diclofenac, 75 mg twice daily, in patients with rheumatoid arthritis.82 *P <
Gastroenterology  , DOI: ( /gast )
Copyright © 2001 American Gastroenterological Association Terms and Conditions